Navitoclax Plus Dabrafenib and Trametinib Shows Activity in BRAF-Mutant Melanoma
Source: Cancer Therapy Advisor, June 2023
Combination treatment with dabrafenib, trametinib, and navitoclax has demonstrated activity in patients with BRAFV600-mutant, advanced melanoma, according to research presented at the ASCO Annual Meeting 2023.
The combination produced a complete response (CR) rate of 20% in a phase 2 trial. However, the 3-drug combination did not improve maximal tumor regression when compared to treatment with dabrafenib and trametinib.
The phase 2 trial (ClinicalTrials.gov Identifier: NCT01989585) included 50 patients with BRAFV600-mutant, advanced melanoma who had received prior treatment but could not have received BRAF inhibitors.